Comparative Pharmacology
Head-to-head clinical analysis: NORPACE versus PROCAINAMIDE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORPACE versus PROCAINAMIDE HYDROCHLORIDE.
NORPACE vs PROCAINAMIDE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Class Ic antiarrhythmic agent; blocks voltage-gated sodium channels, slowing conduction velocity and prolonging refractory periods in cardiac tissue.
Class Ia antiarrhythmic agent; blocks sodium channels, slowing conduction velocity and prolonging refractory period in atrial and ventricular myocardium.
150 mg orally every 6 hours (maximum 300 mg per dose), extended-release formulation 300 mg every 12 hours.
Oral: 250-500 mg every 3-6 hours. IV: Loading dose 15-18 mg/kg infused over 25-30 minutes, then maintenance infusion 1-4 mg/min. Maximum total daily dose: 4 g.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours (normal renal function); prolonged in renal impairment (up to 24 hours).
Terminal elimination half-life: 2.5-5 hours (normal renal function); prolonged to 11-20 hours in renal impairment (e.g., CrCl <30 mL/min); clinical context: requires dosing adjustment in renal failure; NAPA half-life: 6-8 hours (normal), up to 40 hours in renal failure.
Renal: 40-60% unchanged; biliary/fecal: minor (10-20%).
Renal: ~50-60% unchanged via glomerular filtration and tubular secretion; hepatic metabolism to N-acetylprocainamide (NAPA, active) accounts for ~15-30% of dose, further eliminated renally; biliary/fecal: negligible (<5%).
Category C
Category A/B
Antiarrhythmic (Class Ia)
Antiarrhythmic (Class Ia)